Condition: Advanced Solid Tumours · Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
This description comes directly from the study's public registry record.
Venkateshan Srirangam Prativadibhayankara, MD · +65 6407 4213 · Venkateshan_Srirangam@eddc.sg
Veronica Diermayr · +65 6407 0706 · Veronica_Diermayr@eddc.sg
Always discuss trial participation with your own doctor first.
| University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center | Aurora, Colorado, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| National University Hospital - Medical Oncology | Singapore, South West, Singapore | Recruiting |
| National Cancer Centre Singapore | Singapore, South West, Singapore | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taipei, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05701527